Immune Signatures Identify Patient Subsets Deriving Long-Term Benefit From First-Line Rituximab in Follicular Lymphoma.

ABSTRACT:

Background

The role of first-line single-agent rituximab immunotherapy in follicular lymphoma (FL) remains debated, as most patients eventually undergo chemotherapy.

Methods

In this study, we retrospectively analyzed 81 FL patients treated with first-line single-agent rituximab monotherapy with (n = 53) or without (n = 28) consolidation. Fifty-one patients (63%) were high-tumor burden according to Group d'Etude des Lymphomes Folliculaires (GELF) criteria.

Results

After a median follow-up of 11 years, overall survival (OS) and progression-free survival (PFS) rates were 85% and 32%, respectively. Targeted gene expression profiling (T-GEP) was performed in 40 patients, revealing a 26-gene expression signature distinguishing complete responders and non-respo

SUBMITTER: Lolli G 

PROVIDER: S-EPMC11804214 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature